
Remote consultations work until a clinician needs a blood value. Then your service has a problem. Diagnostics as a Service is one answer to that problem, and a referral is the other. With a referral the person is told to go somewhere else for the draw. Your platform then finds out later whether they went.
Before a platform chooses between those two answers, it has to know what the German rules let a remote service do at all. This article sets that out, starting with what a purely remote consultation may do. It then covers how much of a practice's work may be done by video, and whether a clinician may order a blood test for somebody seen only on screen. It ends with the kit, because a kit that goes out under your own brand raises a question about who counts as its maker.
The rules for doctors allow it, within limits. The model professional code allows treatment purely through communication media in the individual case.1 Three conditions apply. The treatment has to be medically justifiable, the required standard of care has to be kept, and the person has to be told what is different about a remote consultation.1
That code is a model rather than the law itself. Each state medical chamber adopts its own version, so the binding text for your clinicians is the one their own chamber has adopted.
Advertising a remote service is allowed within a narrower limit. The advertising law bans promoting remote treatment unless generally recognised professional standards say a face to face contact is not needed for that condition. The Bundesgerichtshof applied exactly that limit when it ruled against an advertisement that offered remote treatment across conditions in general.2
A purely remote service in Germany may consult, diagnose and treat in the individual case, prescribe, refer and certify short sick leave. It may not advertise remote treatment in general terms. Sources: section 7 paragraph 4 of the model professional code, section 9 of the Heilmittelwerbegesetz, and the Bundesgerichtshof judgment of 9 December 2021.
Up to half of a practice's work. Since 1 April 2025 a practice may treat up to half of its treatment cases each quarter purely by video. The limit counts only cases handled entirely by video. It applies per practice location, and it leaves out emergencies and people who are also seen in person.3
How much is allowed is one question. How much is actually done is a separate question, which the published count answers. The Zentralinstitut für die kassenärztliche Versorgung counted 3.2 million statutory video consultations in 2025, which was 17.9 percent more than in 2024.4
The published guidance says it can be permissible. The Bundesärztekammer states that a referral during purely remote treatment can be permissible where the professional rule is observed alongside the ordinary referral rules of the collective agreement.5
Whether that holds in a given consultation is a judgement for the treating clinician and their state chamber. A supplier does not make that judgement.
Two caveats belong with that guidance. The first is that it speaks about referrals in general rather than about laboratory orders by name. The second concerns privately insured people, because the terms of their own policy may restrict what is covered.5
The professional rule gives one more reason to read a test order as permitted. It names the taking of findings among the care that has to be kept in a remote consultation.1 A blood test is one way of taking findings.
Read together with the guidance above, ordering a test is one way a remote consultation keeps that standard of care rather than a way around the rule. Neither document says that in those words, so treat it as our reading. The state chamber is the body that settles it.
It can, depending on the label. Under the European rules for diagnostic devices, a distributor takes on the manufacturer's duties when it makes a device available under its own name or trade mark.6
A kit that goes out under your brand alone therefore makes you the maker in law. The same article allows one way out. Where an agreement names the original maker on the label and keeps that maker responsible for the maker's requirements, the distributor stays a distributor.6 Whether a particular agreement does that is a question for your own regulatory adviser.
If the kit carries the original maker's name and an agreement leaves the duties with them, the platform is a distributor. Under the platform's own brand, the platform takes on the maker's duties. Sources: Regulation (EU) 2017/746, Articles 16(1)(a) and 48(10), and MDCG 2020-16 revision 5 of September 2026.
Two further points decide how heavy the maker's duties are for this kind of kit.
So the kit question is a branding decision with a regulatory consequence. Decide it before the first kit is printed rather than discovering it afterwards.
The clinical responsibility stays with you. A supplier does not take on the clinical decision, the prescription, or the duty to meet the professional standard in the individual case. Those belong to whoever runs the consultation.
The questions follow the stages of a build, so they are set out in that order.
The last question is the one a real case will test. Its answer belongs in the contract rather than in the onboarding call.
The consultation ends where your clinician decides a blood value is needed. Aniva begins at that point, when your clinician orders inside your own product. The collection, the accredited laboratory work and the result then run as one service that delivers the result back into your product. The network that collects the sample is Aniva's own rather than a subcontractor's.
At no point does a user meet the Aniva brand. Whose name goes on the kit is a separate choice that belongs with your own regulatory advice and with the agreement you sign.
Book a demo if you want to see the ordering, the kit and the result as your interface would receive it.
This article describes German professional rules and European device rules as they affect a telemedicine service buying blood testing. It is general information and not legal advice, and your own arrangement is a question for your own adviser.

Aniva handles the lab, the logistics and the report. You keep the patient relationship and your own branding.
Twenty minutes, and you will know whether it fits your setup.